Marketing & Communications

Danica Patrick paces health system marketing drive

The driver on NASCAR and other racing circuits will help challenge consumers to improve their health habits.

EHRs blur line between marketing and assistance: researchers

EHRs blur line between marketing and assistance: researchers

By

A trio of doctors make a case for putting limits on digital promotions, including those in EHRs and through social networks.

Acthar marketing drives prescriptions and anger

The decades-old drug is winning prescriptions through marketing, but has a free-pass when it comes to clinical trial data.

Rep access continues to shrink

Rep access continues to shrink

By

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Vet drugmakers get Warning Letters too

Regulatory Focus reports that the regulator has issued a Warning Letter to AB Science for marketing its canine tumor drug Kinavet for unapproved, off-label uses.

Marketing tone sinks GSK recruiter

GlaxoSmithKline dismissed a marketer over its approach to clinical trial recruiting.

Takeda walks away from Omontys

The drugmaker is pulling its US marketing application for the anemia drug.

Study: sales rep limits reduce off-label prescriptions

Study: sales rep limits reduce off-label prescriptions

By

Researchers found that limiting sales rep access and interactions reduces off-label prescriptions for the previously detailed drugs, while also upping off-label prescriptions of the drugs that had not been promoted.

OPDP takes on sales aid for alcohol drug

OPDP takes on sales aid for alcohol drug

By

The advertising watchdog gave drugmaker Alvogen 15 days to make amends.

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

By

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Court reverses Risperdal decision

The Arkansas Supreme Court's decision puts $1.2 billion back into J&J's coffers.

Agnitio launches Rainmaker marketing tool

Agnitio launches Rainmaker marketing tool

By

The company unveiled the mix-and-match marketing management tool at the Eye for Pharma conference in Barcelona.

DOJ may cost Aegerion patients

The drugmaker's annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.

US Attorney scrutinizes Copaxone marketing

The US Attorney's Office for the Southern District of New York is examining how Teva has marketed MS drug Copaxone and Parkinson's medication Azilect since 2006.

E-mail increasingly read on mobile devices

Movable Ink reports that 65% of Q4 emails were opened on a tablet or smartphone.

Roche silences Herceptin comparison

A court in India ruled biosimilar drug makers will not be able to cite the drug's name, efficacy or safety profile in its marketing.

UK GPs like search engines more than pharma sites

A survey of UK-based general practitioners shows industry websites are not a go-to source for information. Reps did not fare well, either.

Louisiana chucks Risperdal settlement

An appeals court says J&J does not have to pay $257.7 million.

Weight-loss drugs plateau and expand

Weight-loss drugs plateau and expand

By

Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.

Dept. of Justice subpoenas Aegerion

Dept. of Justice subpoenas Aegerion

By

The drugmaker announced Friday that the DOJ wants documents regarding sales and marketing of Juxtapid, its drug for an ultra-rare lipid disorder.

Draft legislation has advertisers on edge

Draft legislation has advertisers on edge

By

Lobbying groups say the ad tax draft proposal could wreak havoc throughout the ad industry and its partners, such as publishers and broadcasters, if it were to go through.

NYT picks apart ADHD

The Gray Lady surveys the landscape of attention deficit disorder marketing.

OPDP not happy with Diclegis promo

OPDP not happy with Diclegis promo

By

The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.

OIG subpoenas United Therapeutics paperwork

The government division is scrutinizing marketing information for three drugs.

Aranesp mailer catches OPDP's attention

Aranesp mailer catches OPDP's attention

By

The marketing watchdog's untitled letter says a direct mailer failed to disclose "material facts" from the warnings and precautions section of the PI.

OPDP letter dings Kadmon for previous violation

OPDP letter dings Kadmon for previous violation

By

The agency's bad-ad warning letter calls the new violations "particularly troubling."

Researcher finds black-box drugs have high Warning Letter risk

EyeonFDA finds that, when it comes to black-boxed drugs' marketing materials, the FDA is more likely to issue Warning Letters than untitled letters.

Ariad hunkers down

Ariad hunkers down

By

The drugmaker's latest financial plans could power it through mid-2015.

Co-pay cards OK for exchanges

Subscribers will be able to use co-pay cards on Obamacare exchanges.

Ariad pulls Iclusig from the market after FDA request

Ariad pulls Iclusig from the market after FDA request

By

The drug company is ceasing US distribution and marketing the leukemia drug after the FDA said it was worried about blood clots among clinical trial patients.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters